476 related articles for article (PubMed ID: 25616728)
1. Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy.
Kim YK; Ryoo NK; Woo SJ; Park KH
Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2063-73. PubMed ID: 25616728
[TBL] [Abstract][Full Text] [Related]
2. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Cheng CK; Chang CK; Peng CH
Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
[TBL] [Abstract][Full Text] [Related]
3. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
Matušková V; Vysloužilová D; Uher M
Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
[TBL] [Abstract][Full Text] [Related]
4. Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
Smretschnig E; Ansari-Shahrezaei S; Hagen S; Glittenberg C; Krebs I; Binder S
Retina; 2013 Feb; 33(2):316-23. PubMed ID: 23314238
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of photoreceptor loss and recovery after half-fluence photodynamic therapy for chronic central serous chorioretinopathy.
Gutiérrez-Hernández JC; Martínez-Camarillo JC; Sadda SR
Retin Cases Brief Rep; 2015; 9(2):109-13. PubMed ID: 25383847
[TBL] [Abstract][Full Text] [Related]
6. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy.
Nicoló M; Eandi CM; Alovisi C; Grignolo FM; Traverso CE; Musetti D; Cardillo Piccolino F
Am J Ophthalmol; 2014 May; 157(5):1033-7. PubMed ID: 24487046
[TBL] [Abstract][Full Text] [Related]
7. Comparison of half-dose photodynamic therapy and 689 nm laser treatment in eyes with chronic central serous chorioretinopathy.
Russo A; Turano R; Morescalchi F; Gambicorti E; Cancarini A; Duse S; Costagliola C; Semeraro F
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1141-1148. PubMed ID: 28283732
[TBL] [Abstract][Full Text] [Related]
8. Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.
Sheptulin V; Purtskhvanidze K; Roider J
Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2027-2034. PubMed ID: 30097783
[TBL] [Abstract][Full Text] [Related]
9. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
Bae SH; Heo J; Kim C; Kim TW; Shin JY; Lee JY; Song SJ; Park TK; Moon SW; Chung H
Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858
[TBL] [Abstract][Full Text] [Related]
10. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy.
Bae SH; Heo JW; Kim C; Kim TW; Lee JY; Song SJ; Park TK; Moon SW; Chung H
Am J Ophthalmol; 2011 Nov; 152(5):784-92.e2. PubMed ID: 21742303
[TBL] [Abstract][Full Text] [Related]
11. Half-fluence photodynamic therapy in acute central serous chorioretinopathy.
Smretschnig E; Ansari-Shahrezaei S; Moussa S; Glittenberg C; Krebs I; Binder S
Retina; 2012; 32(10):2014-9. PubMed ID: 22466482
[TBL] [Abstract][Full Text] [Related]
12. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy.
Lim JI; Glassman AR; Aiello LP; Chakravarthy U; Flaxel CJ; Spaide RF;
Ophthalmology; 2014 May; 121(5):1073-8. PubMed ID: 24439758
[TBL] [Abstract][Full Text] [Related]
13. [Observation on long-term efficacy of half-dose photodynamic therapy with chronic central serous chorioretinopathy using optical coherence tomography].
Liu Y; Li L; Xu G; Wang W
Zhonghua Yan Ke Za Zhi; 2016 May; 52(5):328-34. PubMed ID: 27220704
[TBL] [Abstract][Full Text] [Related]
14. Detection of morphologic alterations by spectral-domain optical coherence tomography before and after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy.
Shinojima A; Kawamura A; Mori R; Fujita K; Yuzawa M
Retina; 2011 Oct; 31(9):1912-20. PubMed ID: 21952105
[TBL] [Abstract][Full Text] [Related]
15. Half-dose Versus Half-time Photodynamic Therapy for Central Serous Chorioretinopathy.
Liu HY; Yang CH; Yang CM; Ho TC; Lin CP; Hsieh YT
Am J Ophthalmol; 2016 Jul; 167():57-64. PubMed ID: 27084002
[TBL] [Abstract][Full Text] [Related]
16. Foveal and Extrafoveal Effects of Half-Dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy: A Cohort Study.
Pinto C; Sousa K; Oliveira E; Mendonça L; Gentil R; Queirós L; Falcão M
Semin Ophthalmol; 2022 Feb; 37(2):153-157. PubMed ID: 34027797
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
Son BK; Kim K; Kim ES; Yu SY
Ophthalmologica; 2019; 241(2):105-115. PubMed ID: 30110697
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Focal and Conventional Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
Noh SR; Kang MS; Kim K; Kim ES; Yu SY
Korean J Ophthalmol; 2019 Dec; 33(6):506-513. PubMed ID: 31833247
[TBL] [Abstract][Full Text] [Related]
19. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial.
Reibaldi M; Cardascia N; Longo A; Furino C; Avitabile T; Faro S; Sanfilippo M; Russo A; Uva MG; Munno F; Cannemi V; Zagari M; Boscia F
Am J Ophthalmol; 2010 Feb; 149(2):307-315.e2. PubMed ID: 19896635
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy.
van Rijssen TJ; van Dijk EHC; Dijkman G; Boon CJF
Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1395-1402. PubMed ID: 29732468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
